Overview Upon MiR-21 in Lung Cancer: Focus on NSCLC

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2018 Jul 22

PMID 30030592

Citations 120

Authors

Cecilia Bica-Pop

Roxana Cojocneanu-Petric

Lorand Magdo

Lajos Raduly

Diana Gulei

Ioana Berindan-Neagoe

Affiliations

Soon will be listed here.

Abstract

Considering the high mortality rate encountered in lung cancer, there is a strong need to explore new biomarkers for early diagnosis and also improved therapeutic targets to overcome this issue. The implementation of microRNAs as important regulators in cancer and other pathologies expanded the possibilities of lung cancer management and not only. MiR-21 represents an intensively studied microRNA in many types of cancer, including non-small cell lung cancer (NSCLC). Its role as an oncogene is underlined in multiple studies reporting the upregulated expression of this sequence in patients diagnosed with this malignancy; moreover, several studies associated this increased expression of miR-21 with a worse outcome within NSCLC patients. The same pattern is supported by the data existent in the Cancer Genome Atlas (TCGA). The carcinogenic advantage generated by miR-21 in NSCLC resides in the target genes involved in multiple pathways such as cell growth and proliferation, angiogenesis, invasion and metastasis, but also chemo- and radioresistance. Therapeutic modulation of miR-21 by use of antisense sequences entrapped in different delivery systems has shown promising results in impairment of NSCLC. Hereby, we review the mechanisms of action of miR-21 in cancer and the associated changes upon tumor cells together a focused perspective on NSCLC signaling, prognosis and therapy.

Citing Articles

The correlation between miR-21 single nucleotide polymorphisms and the susceptibility of non-small cell lung cancer.

Zhang M, Zhang M, Han R, Yu X, Song Z J Cardiothorac Surg. 2025; 20(1):76.

PMID: 39833839 PMC: 11748343. DOI: 10.1186/s13019-024-03322-5.

MicroRNA Significance in Cancer: An Updated Review on Diagnostic, Prognostic, and Therapeutic Perspectives.

Singh V, Sen A, Saini S, Dwivedi S, Agrawal R, Bansal A EJIFCC. 2025; 35(4):265-284.

PMID: 39810890 PMC: 11726331.

Cutaneous squamous cell carcinoma-derived exosomal MicroRNA-31 acts as an oncogene by targeting the tumor suppressor RhoBTB1.

Mu Y, Lian C, Chen X, Yang X, Li D, Zhang Y Arch Dermatol Res. 2024; 317(1):114.

PMID: 39673615 DOI: 10.1007/s00403-024-03558-0.

MiR-21-5p Modulates Cisplatin-Resistance of CD44+ Gastric Cancer Stem Cells Through Regulating the TGF-β2/SMAD Signaling Pathway.

Nie X, Liu J, Wang D, Li C, Teng Y, Li Z Int J Gen Med. 2024; 17:4579-4593.

PMID: 39411053 PMC: 11476341. DOI: 10.2147/IJGM.S476647.

Regulation of idiopathic pulmonary fibrosis: a cross-talk between TGF- signaling and MicroRNAs.

Wang S, Yu H, Liu S, Liu Y, Gu X Front Med (Lausanne). 2024; 11:1415278.

PMID: 39386739 PMC: 11461268. DOI: 10.3389/fmed.2024.1415278.

References

Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

Ananta J, Paulmurugan R, Massoud T . Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy. Mol Pharm. 2016; 13(9):3164-75. DOI: 10.1021/acs.molpharmaceut.6b00388. View

Tian L, Shan W, Zhang Y, Zhnag Y, Lv X, Li X . Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer. Pathol Oncol Res. 2015; 22(1):161-7. DOI: 10.1007/s12253-015-9979-7. View

Lin L, Tu H, Wu L, Liu M, Jiang G . MicroRNA-21 Regulates Non-Small Cell Lung Cancer Cell Invasion and Chemo-Sensitivity through SMAD7. Cell Physiol Biochem. 2016; 38(6):2152-62. DOI: 10.1159/000445571. View

Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P . Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010; 90(2):144-55. DOI: 10.1038/labinvest.2009.126. View

Jiang S, Wang R, Yan H, Jin L, Dou X, Chen D . MicroRNA-21 modulates radiation resistance through upregulation of hypoxia-inducible factor-1α-promoted glycolysis in non-small cell lung cancer cells. Mol Med Rep. 2016; 13(5):4101-7. DOI: 10.3892/mmr.2016.5010. View

Dong J, Zhang Z, Gu T, Xu S, Dong L, Li X . The role of microRNA-21 in predicting brain metastases from non-small cell lung cancer. Onco Targets Ther. 2017; 10:185-194. PMC: 5207466. DOI: 10.2147/OTT.S116619. View

Zhu J, Qi Y, Wu J, Shi M, Feng J, Chen L . Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. Oncol Lett. 2017; 12(6):4829-4837. PMC: 5228282. DOI: 10.3892/ol.2016.5295. View

DUrso P, DUrso O, Damiano Gianfreda C, Mezzolla V, Storelli C, Marsigliante S . miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma. Curr Genomics. 2016; 16(5):304-11. PMC: 4763968. DOI: 10.2174/1389202916666150707155610. View

10.

Li C, Yin Y, Liu X, Xi X, Xue W, Qu Y . Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance. Oncotarget. 2017; 8(15):24564-24578. PMC: 5421870. DOI: 10.18632/oncotarget.15596. View

11.

Zhong Z, Dong Z, Yang L, Gong Z . miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. J Cancer Res Clin Oncol. 2012; 138(10):1781-8. DOI: 10.1007/s00432-012-1287-y. View

12.

Zhang J, Zhang C, Hu L, He Y, Shi Z, Tang S . Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated with Radioresistance of Lung Cancer. Cancer Invest. 2015; 33(5):165-71. DOI: 10.3109/07357907.2015.1019676. View

13.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

14.

Gallo A, Tandon M, Alevizos I, Illei G . The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7(3):e30679. PMC: 3302865. DOI: 10.1371/journal.pone.0030679. View

15.

Gui F, Hong Z, You Z, Wu H, Zhang Y . MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway. Cell Biol Int. 2016; 40(12):1294-1302. DOI: 10.1002/cbin.10678. View

16.

Castanotto D, Rossi J . The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009; 457(7228):426-33. PMC: 2702667. DOI: 10.1038/nature07758. View

17.

Jiang L, He C, Zhu Z . Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene. Oncotarget. 2017; 8(14):23675-23689. PMC: 5410336. DOI: 10.18632/oncotarget.15644. View

18.

Yin J, Park G, Lee J, Choi E, Park J, Kim T . DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis. Brain. 2015; 138(Pt 9):2553-70. DOI: 10.1093/brain/awv167. View

19.

Guo X, Lv X, Lv X, Ma Y, Chen L, Chen Y . Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. 2017; 8(27):44050-44058. PMC: 5546461. DOI: 10.18632/oncotarget.17211. View

20.

Wang W, Zhang H, Wang L, Ma Y, Gao F, Zhang S . miR-21 expression predicts prognosis in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2014; 38(6):715-9. DOI: 10.1016/j.clinre.2014.07.001. View